New drug combination for relapsed or refractory t-cell and nk-cell lymphomas
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called zeprumetostat (an EZH2 inhibitor) combined with other treatments for people with mature T-cell or NK-cell lymphoma that has come back or not responded to standard therapy. The goal is to see if the combination can help control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of mature T-cell or NK-cell lymphoma.
- Your lymphoma must have at least one measurable or evaluable lesion (a spot that can be measured or seen on scans).
- You must have tried standard treatment and it failed, stopped working, or you couldn't tolerate it. (If you have ALCL, you must have had a specific drug called anti-CD30; if you have NKTCL, you must have had pegaspargase or L-asparaginase.)
- You should be able to care for yourself (ECOG performance status 0-2).
- Your organs and bone marrow must be functioning well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (tislelizumab and zeprumetostat) for people whose NK/T-cell lymphoma has returned or stopped responding to previous treatment. The goal is to see if the combination works better than what has been tried before.
This trial tests a new combination of targeted drugs (including an EZH2 inhibitor) for people with peripheral T-cell lymphoma (PTCL) that didn't respond to their first treatment. The drugs are chosen based on the genetic mutations in your tumor, aiming to attack the cancer more precisely.
This study tests a new drug, zeprumetostat, combined with other treatments for people with a type of lymphoma that has come back or not responded to previous therapy. The goal is to see if these combinations can help control the cancer.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This early-stage study tests a new pill (zeprumetostat) for people with a rare type of leukemia (T-LGLL) that has not improved after initial treatment. The goal is to see if it can safely improve blood counts and relieve symptoms.
This study tests a new combination of drugs for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The combination includes an experimental drug (EZH2i), an immunotherapy (glofitamab), and chemotherapy (GemOx), all given together to see if it is safe and effective.
Hear when a new Mature T-cell and NK-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.